Pfizer stumbles close to finish line in growth hormone race, extending the lead of rival Ascendis

Pfizer’s bid to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back approval of Pfizer’s once-weekly prospect, giving rival Ascendis Pharma a longer window in which to convert physicians and patients from current daily options without competition.